Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis - Scorecard - MDSpire

Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

  • By

  • Thomas P. Lodise

  • Nicholas A. Turner

  • Toshimitsu Hamasaki

  • Nick Fishbane

  • Varduhi Ghazaryan

  • Alison Wall

  • Lizhao Ge

  • Qihang Wu

  • Lijuan Zeng

  • Todd Riccobene

  • Rinal Patel

  • Smitha Zaharoff

  • Urania Rappo

  • Scott Evans

  • Vance G. Fowler

  • Henry F. Chambers

  • Thomas L. Holland

  • Antibacterial Resistance Leadership Group

  • Robin Patel

  • Heather Cross

  • Anthony Harris

  • Melinda Pettigrew

  • David van Duin

  • Helen Boucher

  • Clayton Huntley

  • Erica Raterman

  • Tamika Samuel

  • Kyung Moon

  • Kim Hanson

  • Yohei Doi

  • Tom Lodise

  • Ritu Banerjee

  • Sara Cosgrove

  • David Paterson

  • Ebbing Lautenbach

  • Maureen Mehigan

  • Sarah Doernberg

  • Sam Perdue

  • April 18, 2026

  • 0 min

Share

Clinical Scorecard: Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

At a Glance

CategoryDetail
ConditionComplicated Staphylococcus aureus bacteremia
Key MechanismsDalbavancin is a long-acting lipoglycopeptide antibiotic with a 14-day terminal half-life, active against MRSA, providing sustained plasma levels with two 1500-mg doses one week apart.
Target PopulationAdults with complicated Staphylococcus aureus bacteremia after bloodstream clearance
Care SettingHospital and outpatient settings requiring intravenous antibiotic therapy

Key Highlights

  • Dalbavancin dosing of two 1500-mg intravenous doses one week apart achieves sustained plasma concentrations for 4 to 6 weeks.
  • Population pharmacokinetic modeling used a 3-compartment model with zero-order input and first-order elimination to characterize dalbavancin disposition.
  • Dalbavancin demonstrated noninferiority to standard intravenous antibiotic therapy in the DOTS randomized clinical trial.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of complicated S aureus bacteremia requires blood culture confirmation and clinical assessment of infection complexity.

Management

  • Dalbavancin can be used as consolidation therapy following bloodstream clearance with a dosing regimen of 1500 mg IV on day 1 and day 8 (adjusted to 1125 mg for creatinine clearance <30 mL/min without dialysis).
  • Standard intravenous antibiotic therapy remains an alternative treatment option.

Monitoring & Follow-up

  • Plasma dalbavancin concentrations can be monitored at specified intervals (day 1, 8, 22, 42, and 70) to assess pharmacokinetics and exposure.
  • Renal function should be monitored to guide dose adjustments.

Risks

  • Prolonged intravenous access for standard therapy risks thrombosis, secondary infection, and patient discomfort.
  • Dalbavancin protein binding and pharmacokinetics may vary among individuals, necessitating consideration of patient-specific factors.

Patient & Prescribing Data

Adults with complicated S aureus bacteremia post bloodstream clearance, including those with renal impairment.

Two-dose dalbavancin regimen provides sustained antibiotic exposure with potential for outpatient management, reducing risks associated with prolonged intravenous therapy.

Clinical Best Practices

  • Use population pharmacokinetic modeling to individualize dalbavancin dosing and optimize exposure.
  • Adjust dalbavancin dose in patients with creatinine clearance <30 mL/min who are not on dialysis.
  • Consider dalbavancin as a consolidation therapy option after clearance of bloodstream infection in complicated S aureus bacteremia.
  • Collect plasma samples at defined time points to monitor drug levels and ensure therapeutic exposure.
  • Assess patient factors such as renal function and protein binding variability to guide therapy.

References

Original Source(s)

Pharmacokinetic Profile of Dalbavancin in Complicated Bacteremia Caused by Staphylococcus aureus: A Secondary Analysis

  • by Thomas P. Lodise, Nicholas A. Turner, Toshimitsu Hamasaki, Nick Fishbane, Varduhi Ghazaryan, Alison Wall, Lizhao Ge, Qihang Wu, Lijuan Zeng, Todd Riccobene, Rinal Patel, Smitha Zaharoff, Urania Rappo, Scott Evans, Vance G. Fowler, Henry F. Chambers, Thomas L. Holland, Antibacterial Resistance Leadership Group, Robin Patel, Heather Cross, Anthony Harris, Melinda Pettigrew, David van Duin, Helen Boucher, Clayton Huntley, Erica Raterman, Tamika Samuel, Kyung Moon, Kim Hanson, Yohei Doi, Tom Lodise, Ritu Banerjee, Sara Cosgrove, David Paterson, Ebbing Lautenbach, Maureen Mehigan, Sarah Doernberg, Sam Perdue

  • April 18, 2026

Related Content

Bacteriological Characteristics of Early-Onset Compared to Late-Onset Neonatal Sepsis in a Tertiary Care Facility in Nepal

Evaluation of antibiotic consumption and resistance patterns among neonates: a 10-year retrospective study

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials